Talaporfin sodium
Sponsors
Light Sciences Oncology, University of California, Irvine
Conditions
Benign Prostatic HyperplasiaCarcinoma, HepatocellularColorectal NeoplasmsLiver MetastasesLiver NeoplasmsLower Urinary Tract SymptomsNeoplasm MetastasisNeoplasm Recurrence, Local
Phase 1
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
CompletedNCT00122876
Start: 2005-04-30End: 2006-10-31Target: 25Updated: 2007-12-07
Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
CompletedNCT00709488
Start: 2008-06-30End: 2011-04-30Updated: 2012-11-16
Novel Treatment for Port Wine Stain Birthmarks
CompletedNCT01924273
Start: 2013-06-30End: 2017-07-03Updated: 2022-11-01
Phase 2
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
CompletedNCT00918034
Start: 2009-05-31End: 2011-02-28Updated: 2012-11-16
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
CompletedNCT02326454
Start: 2014-11-30End: 2017-03-29Updated: 2018-08-08
Phase 3
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
CompletedNCT00355355
Start: 2006-07-31End: 2012-09-30Updated: 2015-01-30
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
CompletedNCT00440310
Start: 2007-02-28End: 2011-10-31Updated: 2015-08-25